Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer

被引:52
|
作者
Cron, Kyle R. [1 ]
Zhu, Kaya [1 ]
Kushwaha, Deepa S. [1 ]
Hsieh, Grace [1 ]
Merzon, Dmitry [1 ]
Rameseder, Jonathan [2 ]
Chen, Clark C. [3 ]
D'Andrea, Alan D. [1 ,4 ]
Kozono, David [1 ]
机构
[1] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[2] MIT, Cambridge, MA 02139 USA
[3] Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA
[4] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
来源
PLOS ONE | 2013年 / 8卷 / 09期
基金
美国国家卫生研究院;
关键词
NF-KAPPA-B; DOUBLE-STRAND BREAKS; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; GENE-EXPRESSION; SOLID TUMORS; BORTEZOMIB; ADENOCARCINOMA; RECOMBINATION; CHEMOTHERAPY;
D O I
10.1371/journal.pone.0073710
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Despite optimal radiation therapy (RT), chemotherapy and/or surgery, a majority of patients with locally advanced non-small cell lung cancer (NSCLC) fail treatment. To identify novel gene targets for improved tumor control, we performed whole genome RNAi screens to identify knockdowns that most reproducibly increase NSCLC cytotoxicity. These screens identified several proteasome subunits among top hits, including the topmost hit PSMA1, a component of the core 20 S proteasome. Radiation and proteasome inhibition showed synergistic effects. Proteasome inhibition resulted in an 80-90% decrease in homologous recombination (HR), a 50% decrease in expression of NF-kappa B-inducible HR genes BRCA1 and FANCD2, and a reduction of BRCA1, FANCD2 and RAD51 ionizing radiation-induced foci. I kappa B alpha RNAi knockdown rescued NSCLC radioresistance. Irradiation of mice with NCI-H460 xenografts after inducible PSMA1 shRNA knockdown markedly increased murine survival compared to either treatment alone. Proteasome inhibition is a promising strategy for NSCLC radiosensitization via inhibition of NF-kappa B-mediated expression of Fanconi Anemia/HR DNA repair genes.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Sensitizing oncogenic mutant p53-expressing non-small cell lung cancer to proteasome inhibitors
    Chougoni, Kranthi Kumar
    Neely, Victoria L.
    Ding, Boxiao
    Oduah, Eziafa
    Nguyen, Khanh
    Hu, Bin
    Koblinski, Jennifer
    Windle, Bradford
    Harada, Hisashi
    Grossman, Steven
    CANCER RESEARCH, 2023, 83 (07)
  • [22] Platinum-induced DNA damage and repair mechanisms in non-small cell lung cancer
    He, Y.
    O'Byrne, K. J.
    Cuffe, S.
    Finn, S.
    Barr, M.
    LUNG CANCER, 2015, 87 : S1 - S1
  • [23] Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer
    Denlinger, CE
    Keller, MD
    Mayo, MW
    Broad, RM
    Jones, DR
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (04): : 1078 - 1086
  • [24] Modulating mitochondria metabolism to radiosensitize KEAP1 mutated non-small cell lung cancer
    Bright, Scott J.
    Kolachina, Rishab
    Ben Kacem, Mariam
    Manandhar, Mandira
    Jones, Philip
    Yap, Timothy A.
    Lin, Steven H.
    Sawakuchi, Gabriel O.
    CANCER RESEARCH, 2024, 84 (01)
  • [25] Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review
    Mao, Xinru
    Lee, Nung Kion
    Saad, Shaban Eljali
    Fong, Isabel Lim
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (02) : 375 - 397
  • [26] The expression of DNA methyltransferases in non-small cell lung cancer
    Reppas, S.
    Paparizou, K.
    Mousafeiris, V.
    Aroukatos, P.
    Nakas, D.
    Chrysanthakoloulos, N.
    Zolota, V.
    Tzelepi, V.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S330 - S331
  • [27] Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells
    Li, Yanhui
    Dong, Su
    Tamaskar, Arya
    Wang, Heather
    Zhao, Jing
    Ma, Haichun
    Zhao, Yutong
    ONCOLOGY RESEARCH, 2020, 28 (05) : 497 - 507
  • [28] Trends in ALK inhibitors for non-small cell lung cancer.
    Meade, Denise
    Ng, Marie
    Alford, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Xue, Chongxiang
    Dong, Huijing
    Chen, Ying
    Lu, Xingyu
    Zheng, Shuyue
    Cui, Huijuan
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (06): : 779 - 788
  • [30] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508